Literature DB >> 2155159

General repression of enhanson activity by the adenovirus-2 E1A proteins.

C Rochette-Egly1, C Fromental, P Chambon.   

Abstract

It has been shown previously that the adenovirus 2 (Ad2) E1A proteins repress activation of transcription by the SV40, polyomavirus and immunoglobulin gene enhancers. Here, we demonstrate that the repression of the SV40 enhancer is not specifically mediated by one of its constituent enhansons and/or proto-enhancers, but that each is subject to repression individually. This inhibitory effect of the E1A proteins is also observed with the AP-1 factor-binding enhansons from the polyomavirus and human metallothionein enhancers, and the MHC class I gene H-2Kb enhanson, which binds the KBF1/H2TF1/TC-IIB protein. Repression by the E1A gene products may, in fact, extend to all enhancer trans-activators, because the transcriptional activities of nuclear receptors (e.g., the estrogen and glucocorticoid receptors), of the yeast enhancer factor GAL4 expressed in HeLa cells, and of chimeric trans-activators (such as GAL-VP16) are all similarly inhibited. The E1A protein domains 2 and 3, including the acidic amino acid stretch that has been shown previously to be necessary for E1A-mediated trans-activation, are not required for repression. These results indicate that the amino-terminal region of the protein, which contains domain 1, plays a crucial role in repression, possibly by interfering in the transcriptional activation process at a step common to all trans-acting enhancer factors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155159     DOI: 10.1101/gad.4.1.137

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  35 in total

1.  A DNA element that regulates expression of an endogenous retrovirus during F9 cell differentiation is E1A dependent.

Authors:  B T Lamb; K Satyamoorthy; D Solter; A Basu; M Q Xu; R Weinmann; C C Howe
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

2.  Promoter-specific trans-activation by the adenovirus E1A12S product involves separate E1A domains.

Authors:  V B Kraus; E Moran; J R Nevins
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

3.  Ability of adenovirus 5 E1A proteins to suppress differentiation of BC3H1 myoblasts correlates with their binding to a 300 kDa cellular protein.

Authors:  J S Mymryk; R W Lee; S T Bayley
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

4.  DNA-binding properties of the E1A-associated 300-kilodalton protein.

Authors:  Y Rikitake; E Moran
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

Review 5.  Tumor necrosis factor regulation of major histocompatibility complex gene expression.

Authors:  D R Johnson; J S Pober
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

6.  Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification.

Authors:  P Yaciuk; E Moran
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

7.  E1A dependent up-regulation of c-jun/AP-1 activity.

Authors:  I Kitabayashi; R Chiu; G Gachelin; K Yokoyama
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

8.  Repression of liver-specific hepatitis B virus enhancer 2 activity by adenovirus E1A proteins.

Authors:  S T Chen; H Su; J K Yee
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation.

Authors:  D V Kalvakolanu; S K Bandyopadhyay; M L Harter; G C Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene.

Authors:  M J Gutch; N C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.